Skip to main content
KoBioLabs, Inc. logo

KoBioLabs, Inc. — Investor Relations & Filings

Ticker · 348150 ISIN · KR7348150004 KO Manufacturing
Open in API
Filings indexed 174 across all filing types
Latest filing 2022-08-01 Board/Management Inform…
Country KR South Korea
Listing KO 348150

About KoBioLabs, Inc.

http://kobiolabs.com/en/

KoBioLabs, Inc. is a biotechnology company that develops innovative microbiome-based therapeutics. The company utilizes its proprietary Smartiome® platform, an integrated system for discovering novel drug candidates that employs AI-driven multi-omics analysis and a comprehensive microbiome library with a reverse-translation approach. KoBioLabs is focused on creating a pipeline of new drugs to treat a range of immune, metabolic, and brain disorders. The company also applies advanced technologies, including a microbe-based drug delivery system (mDDS) and biofoundry techniques, to enhance the efficacy of its treatments and address unmet medical needs.

Recent filings

Filing Released Lang Actions
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of a company's representative director (CEO). It explicitly lists the 'before' and 'after' status of the representative directors, the reason for the change (resignation), and the effective date. This aligns perfectly with the definition for Board/Management Information (MANG).
2022-08-01 Korean
투자판단관련주요경영사항(마이크로바이옴 공동연구 및 제휴계약 체결에 따른 1차 연구비 및 라이선스 옵션비 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the receipt of research fees and license option fees following a partnership agreement with Celltrion. Since this is a specific regulatory disclosure of a material event that does not fit into categories like financial reports, dividends, or board changes, it falls under the general regulatory filing category.
2022-07-29 Korean
투자판단관련주요경영사항(마이크로바이옴 신약 KBL697 미국 FDA 2a 임상시험계획 (시험 계획 변경신청))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a change in a clinical trial plan for a microbiome drug (KBL697) submitted to the US FDA and Australian TGA. Since this is a specific regulatory disclosure regarding clinical trial status and does not fit into the other specialized categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2022-07-18 Korean
투자판단관련주요경영사항(균주 및 균주 관련 기술에 대한 라이선스 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the receipt of licensing fees for specific microbial strains. Since this is a specific regulatory disclosure of a business event (licensing revenue) rather than a financial report, dividend notice, or management change, it falls under the general regulatory filing category.
2022-07-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/DART). This is a standard regulatory filing used to disclose insider transactions or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2022-07-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS). This is a standard regulatory filing used to disclose insider transactions or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2022-07-08 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.